Assess whether a CMO finding is a delay or a refuse-to-file risk (db2eb8)

Situation

A CMO finding is sits with pharmacovigilance medical reviewer because a boxed-warning proposal from the review division hit a mid-size sponsor after a complete response letter. Evidence is advisory-committee question list that exposes a weak secondary endpoint; write the Pharma & Life Sciences CMC and Development Pathways option that extract can carry.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose A CMO finding is a delay / A refuse-to-file risk using advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend A CMO finding is a delay from advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend A CMO finding is a delay from advisory-committee question list that exposes a weak secondary endpoint; A refuse-to-file risk is what the extract actually supports after a boxed-warning proposal from the review division.
• A boxed-warning proposal from the review division never reached the population in advisory-committee question list that exposes a weak secondary endpoint — reopen intake, do not close a CMO finding is.
• Two facts in advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division conflict for pharmacovigilance medical reviewer; hold this CMC and Development Pathways file.

Analysis required

• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a boxed-warning proposal from the review division and write the one fact that would move a CMO finding is for pharmacovigilance medical reviewer.

Recommendation